Research

GPs’ drug treatment for depression by patients’ educational level: registry-based study

Anneli Borge Hansen, Valborg Baste, Oystein Hetlevik, Inger Haukenes, Tone Smith-Sivertsen and Sabine Ruths
BJGP Open 2021; 5 (2): BJGPO-2020-0122. DOI: https://doi.org/10.3399/BJGPO-2020-0122

Abstract

Background Antidepressant drugs are often prescribed in general practice. Evidence is conflicting on how patient education influences antidepressant treatment.

Aim To investigate the association between educational attainment and drug treatment in adult patients with a new depression diagnosis, and to what extent sex and age influence the association.

Design & setting A nationwide registry-based cohort study was undertaken in Norway from 2014–2016.

Method The study comprised all residents of Norway born before 1996 and alive in 2015. Information was obtained on all new depression diagnoses in general practice in 2015 (primary care database) and data on all dispensed depression medication (Norwegian Prescription Database [NorPD]) 12 months after the date of diagnosis. Independent variables were education, sex, and age. Associations with drug treatment were estimated using a Cox proportional hazard model and performed separately for sex.

Results Out of 49 967 patients with new depression (61.6% women), 15 678 were dispensed drugs (30.4% women, 33.0% men). Highly educated women were less likely to receive medication (hazard ratio [HR] = 0.93; 95% confidence interval [CI] = 0.88 to 0.98) than women with low education. No such differences appeared among men. Women aged 20–29 years were more likely to be treated with drugs than those aged 30–59 years, and women aged ≥70 years were more likely to receive drugs (HR = 1.65; 95% CI = 1.54 to 1.77) than those aged 20–29 years. The pattern was similar but less pronounced for men.

Conclusion Educational differences in antidepressant therapy among women may reflect different treatment approaches that clinicians should be aware of to avoid unintended variation. Reasons for this variation and consequences for quality of treatment should be explored.

How this fits in

Medication for the treatment of depression is often prescribed by GPs, but little is known about factors that influence GP depression care. This study showed that highly educated women with a new depression diagnosis received less medication than women with low education, while no such differences appeared among men. Further, the youngest and oldest patients were most likely to receive antidepressant drugs. These differences may reflect different depression care approaches that clinicians should be aware of to avoid inequity in treatment.

Introduction

The use of antidepressant drugs has increased substantially during the 1990s and early 2000s.1–3 With respect to prevalence of depression, studies indicate that women,4,5 older people,6–8 and lower socioeconomic groups9 are at increased risk. Moreover, women are more likely to consult their GP for depression compared with men.10 Whether drug use is equally distributed across population groups, such as higher and lower educated, is poorly examined and findings so far are inconsistent.11–13 With respect to sex and age, some studies indicate that GPs prescribe more depression drug therapy to women and older people than to men and younger people.14,15 However, there is a lack of studies that use a new depression diagnosis to confirm this trend.

GPs play a key role in providing health services to patients with depression. According to guidelines, talking therapy by GP is the first choice of treatment for mild depression.16,17 With increased severity, talking therapy may be combined with medication.16 In Norway, about 80% of antidepressant prescriptions are issued by a GP.14 Large registry-based studies with complete data on diagnoses, depression medication, and population demography may increase the knowledge and awareness about variation in healthcare provision to patients with depression.

The aim of this study was to investigate the association between educational attainment and drug treatment in adult patients with a new diagnosis of depression, and to what extent sex and age influence the association.

Method

Design

A nationwide registry-based cohort study was conducted with data from the Norwegian GP-DEP Study, which investigates pathways of depression care in general practice.18 The cohort comprised all individuals with a new depression diagnosis in general practice in 2015. The cohort was examined regarding dispensing of medication for depression in the 12 months after the first date of depression diagnosis (index date) in 2015.

Data sources

Information from national registries was linked at the individual level, using the unique personal identity number (encrypted) assigned to all residents of Norway. All data were stored and analysed at a safe server at the University of Bergen.

The Control and Reimbursement of Healthcare Claims (KUHR) database stores data on all fee-for-service claims from GPs. For each encounter, the claims contain a GP and patient identifier, date of contact, and one or more diagnoses according to the International Classification of Primary Care, Second Edition (ICPC-2).

The NorPD stores information on all prescription drugs dispensed to patients treated in ambulatory care (www.norpd.no). For each prescription, NorPD contains an encrypted prescriber and patient identifier, date of dispensing, generic drug information (Anatomical Therapeutic Chemical [ATC] code), and any reimbursement code. NorPD lacks information at individual level on medication dispensed to people staying in hospitals or nursing homes.

The Norwegian Patient Registry (NPR) comprises information on all patient contacts with secondary health care, with diagnoses according to the International Classification of Diseases, Tenth Revision (ICD-10).

The National Education Database stores information on the highest level of completed education. While the population registry contains information on sex, year of birth, death, and emigration.

Study population

The source population comprised all inhabitants of Norway born before 1 January 1996 and alive 1 January 2015 (4 017 989 individuals). First, all individuals were identified with a depression diagnosis in general practice (GP consultation with the ICPC-2 code P76 Depression in KUHR) in 2015 (n = 124 948). Second, to establish a cohort of patients with a new diagnosis of depression, washout was conducted of 74 981 patients with a diagnosis of depression in general practice (P76 Depression in KUHR) and/or secondary care (ICD-10 codes F32, F33, F34, or F41.2 in NPR) and/or dispensed drug treatment for depression (NorPD) during 12 months before index date. The resulting study population comprised 49 967 individuals (Figure 1).

Figure 1.
Figure 1. Flowchart illustrating the definition of the study population.

Independent variables

The National Education Database is based on the International Standard Classification of Education.19 Eleven levels were recoded into three categories: low (primary school [grades 1–7] and lower-secondary school [grades ≤8–10]); medium (13 years, upper-secondary school); and high (>13 years, university and higher education). Patient age was recoded into decennial categories.

Outcome

From NorPD all medications reimbursed for the treatment of depression were included: antidepressants (ATC code N06A), selected antiepileptic drugs (N03A), and selected antipsychotic drugs (N05A), dispensed during 12-month follow-up after index date (yes, no). Number of days from index date to first drug dispensing was categorised as 0–7, 8–31, 32–183, and 184–365 days. Since drug treatment was initiated by a GP in 86% of cases, the term 'GP drug treatment' was used.

Statistical analysis

Descriptive statistics was used to examine the distribution of antidepressants, antiepileptics, and antipsychotics among the patients treated with drugs, given by numbers and percentages. Dispensing of medication and time interval from index date to first drug dispensing was provided by numbers and percentages, by educational level, sex, and age category. The associations between drug dispensing and education, sex, and age were examined by χ2 test. Further, Cox proportional hazard models were used to estimate the likelihood of being dispensed medication for the independent variables education, sex, and age. Interactions between education and sex, and between education and age, in the association with drug dispensing were tested in separate Cox proportional hazard models. Follow-up was defined in days from index date to first drug dispensing, and individuals were censored at the time of death, emigration, or end of follow-up, whichever occurred first. The results from the final model were presented stratified by sex (owing to interaction), both crude and adjusted, as HRs with 95% CIs. Reference groups were low education and age group 20–29 years.

The association between educational level and time to first drug dispensing was illustrated by Kaplan–Meier survival curves, and a pairwise log rank test was used to test the equality of the distribution of the survival curves between different education levels, and for sex separately. Missing data on education (1.1%) were excluded in the analyses. For all statistical analyses, α = 0.05 was used as significance level. IBM SPSS Statistics software was used (version 25).

Results

The study population comprised 49 967 individuals with a new depression diagnosis in 2015, with a mean age of 44.4 years (standard deviation = 16.2 years); 30 775 (61.6%) women and 19 192 (38.4%) men. Among all patients, 30.1% had low education, 40.1% medium, and 28.1% high (Table 1). The study population comprised a relatively higher proportion of men and younger age groups compared with the washed-out population (see Supplementary Table S1).

View this table:
Table 1. Drug treatment for patients with a new depression diagnosis in 2015, and time from date of diagnosis to first drug dispensing, by education, sex, and age

Among the study population, 15 678 (31.4%) were dispensed depression drugs during the 12-month follow-up, 9354 (30.4%) women and 6324 (33.0%) men (Table 1). Of those receiving medication, 85.2% were dispensed antidepressants only, 4.8% antipsychotics only, and 1.2% antiepileptics only, while 8.9% received drugs from two or three therapeutic groups (Table 2). Selective serotonin reuptake inhibitors (SSRIs) made up for 66.0% of the antidepressants (N06A) dispensed.

View this table:
Table 2. Distribution of drug groups dispensed to patients with a new depression diagnosis in 2015 and treated with medication

Medication was more commonly provided to those with low educational level versus high, to men versus women, and to those aged 20–29 years or aged ≥70 years versus other age groups (Table 1). Altogether 8809 patients collected medication within 1 week of index date, corresponding to 56.2% (n = 8809/15 678) of patients treated with drugs, and 17.6% (n = 8809/49 967) of the total study population, respectively (data not shown).

Owing to a significant interaction between education and sex (P = 0.010), the Cox proportional hazard model was performed for men and women separately. Women with high and medium education were less likely to receive drugs (crude HR = 0.94; 95% CI = 0.90 to 0.99, and HR = 0.86; 95% CI = 0.81 to 0.90, respectively) compared with women with low education (reference), Table 3. The age-adjusted estimates were less pronounced but still significant for highly educated women. Among men there was no association between drug treatment and education. There was no interaction between sex and age. Women aged 20–29 years were more likely to be treated with medication compared with those aged 30–59 years, and women aged ≥70 years were even more likely to receive medication (HR = 1.65; 95% CI = 1.54 to 1.77) than those aged 20–29 years. The pattern was similar but less pronounced for men.

View this table:
Table 3. Likelihood of receiving drug treatment among patients with a new depression diagnosis in 2015, by education and age; stratified by sex (N = 49 967)

Figure 2 illustrates the distribution of survival curves for time to first drug dispensing. Women (Figure 2a) with high education were dispensed depression drugs to a lesser extent and later after index date, compared with those with low or medium education (P≤0.001 for both groups). There was also a different distribution between medium and low educated women (P = 0.018). Highly educated men (Figure 2b) had a different distribution of drug dispensing than men with medium education (P = 0.013).

Figure 2.
Figure 2. The association between education level and number of days from index date to first drug dispensing (Kaplan–Meier survival curves) for patients in Norway, aged ≥20 years with a new depression diagnosis in 2015 (N = 49 967).

Discussion

Summary

In a nationwide cohort of patients with a new diagnosis of depression, a gendered pattern was found in the occurrence of depression and in the likelihood of receiving medication by educational level. While GP-diagnosed depression was considerably more prevalent among women, the proportion being treated with drugs was higher among men. Sex modified the relation between education and medication; hence, all analyses were performed separately for men and women. A novel finding was that highly educated women with new depression were significantly less likely to receive medication than lower educated women, even after adjusting for age. No educational differences were found for men. Finally, the youngest and the oldest patients were the age groups most likely to receive depression drugs.

Strengths and limitations

The main strength of this study is the use of complete registry data from the publicly subsidised primary care services in Norway. Linkage of data from five national registries at the individual level provided a unique source of information, eliminating recall bias and selection bias.

Information on GP-diagnosed depression is another strength. A new depression diagnosis was defined as a GP consultation with the ICPC-2 code P76, after a 1-year washout period. However, the individual GPs set the diagnosis and the KUHR database has no formal control on diagnostic categories. Differing coding behaviour may, therefore, challenge the internal validity. However, potential misclassification by the GP would be non-differential and distributed randomly across population groups. Another limitation is lack of information on severity of depression, as ICPC-2 does not allow for such grading. Severity probably influences GPs’ decisions to initiate drug treatment. On the other hand, variation in severity is most likely also distributed evenly across patient educational level, sex, and age.

The NorPD contains complete data on all prescription drugs dispensed. Although the prevalence of prescribed medication for depression may have been slightly underestimated, the use of drug dispensing data is recognised as an acceptable proxy in epidemiological studies.20 Low out-of-pocket payment in Norway makes medication for depression easily available, and it is thus believed that primary non-compliance is low and evenly distributed across population groups. To strengthen the internal validity, drugs reimbursed for the treatment of depression have only been considered, eliminating for example, SSRIs for anxiety disorder and tricyclic antidepressants for adjuvant pain therapy.

Comparison with existing literature

The prevalence of drug therapy for new depression found in the study (one of three patients) is considerably lower than antidepressant prescription rates of 45%–75% reported in studies from European countries.21–23 This discrepancy may be owing to use of a new diagnosis of depression, a strict definition of depression medication, and the use of drug dispensing data in the study. Half of the patients who started on drug treatment collected medication within 1 week after index date. This finding is in line with studies in the Netherlands and Sweden examining the time interval from depression diagnosis to initiation of drug treatment.22,23

Turning to sex, a Swedish registry study also including only newly diagnosed patients with depression found a slightly greater proportion of men than women receiving antidepressant drugs,23 in line with the present study's findings. The lower proportion of women using depression drugs may be related to gendered preferences; women preferring talking therapy, men drug treatment.24–26 On the other hand, GPs may initiate talking therapy to women owing to a preconception that they are more inclined to conversation.

A study in the UK among people aged ≥55 years showed that treatment rates with antidepressants were high for those recorded with a new depression diagnosis but varied little by age.8 The present study indicates that the youngest and oldest patients were most commonly prescribed medication. Higher prescription rates for older people may be an expression of unwarranted variation, since studies suggest that older people judge talking therapy more favourably than medication.27,28 GPs should be aware of older patients’ increased risk of polypharmacy and adverse side effects.29 This practice may nevertheless be owing to brief GP encounters with focus on somatic conditions,27 or to limited access to secondary mental health care.30

Depression is more prevalent among people with low socioeconomic status (SES) compared with those better off.9 Previous studies investigating the relationship between education and antidepressant use have demonstrated divergent findings. In line with the present study's results, a registry-based study in Sweden showed that poorly educated people received more prescriptions of antidepressants than those with higher education; the educational gradient being somewhat stronger among women than among men.12 Accordingly, Packness and colleagues in Denmark found that higher educated groups with no or few self-reported symptoms of depression were less likely to use medication; however, no associations were found among people with more pronounced symptoms.13 In contrast, Kivimäki and colleagues found lesser antidepressant use among men with lower education compared with men with higher education in Finland, while such differences were not seen in women.11 Finally, two studies conducted in Denmark and one in Australia showed no association between education and antidepressant use.31–33 The conflicting results in these studies could be owing to different study populations and measures of educational status, or to cross-national differences in access to treatment among disadvantaged people. In contrast to the current study, none of these studies comprised information on new depression diagnoses made by a GP.

Socioeconomic variation in antidepressant use found in this study may reflect an unintended bias by the GP letting SES influence prescription of medication,33 differential patient preferences supported by the GP, or a combination. One may speculate whether GPs prescribe drugs rather than provide talking therapy to patients they perceive as less educated, or whether better educated patients are more assertive about having non-pharmacological therapy. A survey among patients in GP waiting rooms in Norway showed that lower educational level was associated with greater preference for medication.34 The association between educational level and drug treatment found in the present study among women only, may suggest that highly educated women are more sceptical towards medication in general. This may apply particularly to younger women since older women in the study population were less educated.

Implications for research and practice

The results of the study support an association between drug treatment for new depression and patient sex, education, and age. Highly educated women received less medication than women with low education, and no such differences appeared among men. Educational differences among women may reflect different treatment approaches that clinicians should be aware of to avoid unintended variation. Qualitative studies or register studies with long-time observation of treatment outcomes are needed to further explore the observed variation across educational levels, its reasons, and implications for the quality of depression treatment.

Notes

Funding

Funding for this study was received from the Norwegian Research Fund for General Practice via a PhD grant (Anneli Borge Hansen); the Research Council of Norway (grant reference number: 287884); and NORCE Norwegian Research Centre, Research Unit for General Practice.

Ethical approval

Ethical approval for this study was received from the Regional Committee for Medical and Health Research Ethics (reference number: 2017/934), and Norwegian Data Inspectorate (reference number: 17/01372).

Provenance

Freely submitted; externally peer reviewed.

Acknowledgements

The authors wish to thank Tatiana Fomina at Biostatistics and Data analysis core facility (BIOS) at the University of Bergen for help in facilitating data. The authors further acknowledge Kristian Jansen for British English language editing.

Competing interests

The authors declare that no competing interests exist.

  • Received July 10, 2020.
  • Accepted September 2, 2020.

This article is Open Access: CC BY license (https://creativecommons.org/licenses/by/4.0/)

References

  1. 1.↵
    1. Brugha TS,
    2. Bebbington PE,
    3. Singleton N,
    4. et al.
    (2004) Trends in service use and treatment for mental disorders in adults throughout Great Britain. Br J Psychiatry 185(5):378–384, doi:10.1192/bjp.185.5.378, pmid:15516545.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Bramness JG,
    2. Walby FA,
    3. Tverdal A
    (2007) The sales of antidepressants and suicide rates in Norway and its counties 1980–2004. J Affect Disord 102(1–3):1–9, doi:10.1016/j.jad.2006.12.002, pmid:17223200.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Mojtabai R
    (2008) Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom 77(2):83–92, doi:10.1159/000112885, pmid:18230941.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kringlen E,
    2. Torgersen S,
    3. Cramer V
    (2001) A Norwegian psychiatric epidemiological study. Am J Psychiatry 158(7):1091–1098, doi:10.1176/appi.ajp.158.7.1091, pmid:11431231.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators
    (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159), doi:10.1016/S0140-6736(18)32279-7, pmid:30496104. 1789-1858.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Alexopoulos GS
    (2005) Depression in the elderly. Lancet 365(9475):1961–1970, doi:10.1016/S0140-6736(05)66665-2, pmid:15936426.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Frost R,
    2. Beattie A,
    3. Bhanu C,
    4. et al.
    (2019) Management of depression and referral of older people to psychological therapies: a systematic review of qualitative studies. Br J Gen Pract 69(680):e171–e181, doi:10.3399/bjgp19X701297, pmid:30745355.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Walters K,
    2. Falcaro M,
    3. Freemantle N,
    4. et al.
    (2018) Sociodemographic inequalities in the management of depression in adults aged 55 and over: an analysis of English primary care data. Psychol Med 48(9):1504–1513, doi:10.1017/S0033291717003014, pmid:29017624.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Lorant V,
    2. Deliège D,
    3. Eaton W,
    4. et al.
    (2003) Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol 157(2):98–112, doi:10.1093/aje/kwf182, pmid:12522017.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Wang Y,
    2. Hunt K,
    3. Nazareth I,
    4. et al.
    (2013) Do men consult less than women? An analysis of routinely collected UK general practice data. BMJ Open 3(8), doi:10.1136/bmjopen-2013-003320, pmid:23959757. e003320.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Kivimäki M,
    2. Gunnell D,
    3. Lawlor DA,
    4. et al.
    (2007) Social inequalities in antidepressant treatment and mortality: a longitudinal register study. Psychol Med 37(3):373–382, doi:10.1017/S0033291706009457, pmid:17121686.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Weitoft GR,
    2. Rosén M,
    3. Ericsson O,
    4. et al.
    (2008) Education and drug use in Sweden — a nationwide register-based study. Pharmacoepidemiol Drug Saf 17(10):1020–1028, doi:10.1002/pds.1635, pmid:18720428.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Packness A,
    2. Halling A,
    3. Hastrup LH,
    4. et al.
    (2018) Socioeconomic position, symptoms of depression and subsequent mental healthcare treatment: a Danish register-based 6-month follow-up study on a population survey. BMJ Open 8(10), doi:10.1136/bmjopen-2017-020945, pmid:30287666. e020945.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Kjosavik SR,
    2. Ruths S,
    3. Hunskaar S
    (2009) Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian prescription database. Pharmacoepidemiol Drug Saf 18(7):572–578, doi:10.1002/pds.1756, pmid:19402032.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Thunander Sundbom L,
    2. Hedborg K
    (2019) Association between prescribed antidepressants and other prescribed drugs differ by gender: a nationwide register-based study in Sweden. Nord J Psychiatry 73(1):73–79, doi:10.1080/08039488.2018.1536766, pmid:30661437.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Norwegian Board of Health
    (2009) [National guidelines for diagnosis and treatment of adults with depression] Nasjonale retningslinjer for diagnostisering og behandling av voksne med depresjon (IS–1561) (in Norwegian) (Norwegian Board of Health, Oslo).
  17. 17.↵
    1. National Institute for Health and Clinical Excellence (NICE)
    (2009) Depression in adults: recognition and management. Clinical guideline [CG90]. https://www.nice.org.uk/guidance/cg90/resources/depression-in-adults-recognition-and-management-pdf-975742636741. 3 Feb 2021.
  18. 18.↵
    1. NORCE
    [Depression in general practice] Depresjon i allmennpraksis (in Norwegian). https://www.norceresearch.no/en/projects/depresjon-i-allmennpraksis. 3 Feb 2021.
  19. 19.↵
    1. UNESCO Institute for Statistics
    (2011) International standard classification of education ISCED 2011. http://uis.unesco.org/sites/default/files/documents/international-standard-classification-of-education-isced-2011-en.pdf. 28 Jan 2021.
  20. 20.↵
    1. Beardon PH,
    2. McGilchrist MM,
    3. McKendrick AD,
    4. et al.
    (1993) Primary non-compliance with prescribed medication in primary care. BMJ 307(6908):846–848, doi:10.1136/bmj.307.6908.846, pmid:8401129.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Boffin N,
    2. Bossuyt N,
    3. Declercq T,
    4. et al.
    (2012) Incidence, patient characteristics and treatment initiated for GP-diagnosed depression in general practice: results of a 1-year nationwide surveillance study. Fam Pract 29(6):678–687, doi:10.1093/fampra/cms024, pmid:22523390.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Magnée T,
    2. de Beurs DP,
    3. Schellevis FG,
    4. et al.
    (2018) Antidepressant prescriptions and mental health nurses: an observational study in Dutch general practice from 2011 to 2015. Scand J Prim Health Care 36(1):47–55, doi:10.1080/02813432.2018.1426145, pmid:29338537.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Lytsy P,
    2. Hallqvist J,
    3. Alexanderson K,
    4. et al.
    (2019) Gender differences in healthcare management of depression: aspects of sick leave and treatment with psychoactive drugs in a Swedish setting. Nord J Psychiatry 73(7):441–450, doi:10.1080/08039488.2019.1649723, pmid:31403826.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. McHugh RK,
    2. Whitton SW,
    3. Peckham AD,
    4. et al.
    (2013) Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry 74(6):595–602, doi:10.4088/JCP.12r07757, pmid:23842011.
    OpenUrlCrossRefPubMed
  25. 25.
    1. Ramanuj P,
    2. Ferenchick EK,
    3. Pincus HA
    (2019) Depression in primary care: part 2 — management. BMJ 365:l835, doi:10.1136/bmj.l835, pmid:30962249.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Houle J,
    2. Villaggi B,
    3. Beaulieu M-D,
    4. et al.
    (2013) Treatment preferences in patients with first episode depression. J Affect Disord 147(1–3):94–100, doi:10.1016/j.jad.2012.10.016, pmid:23167975.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Landreville P,
    2. Landry J,
    3. Baillargeon L,
    4. et al.
    (2001) Older adults' acceptance of psychological and pharmacological treatments for depression. J Gerontol B Psychol Sci Soc Sci 56(5):P285–P291, doi:10.1093/geronb/56.5.P285, pmid:11522803.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Gum AM,
    2. Areán PA,
    3. Hunkeler E,
    4. et al.
    (2006) Depression treatment preferences in older primary care patients. Gerontologist 46(1):14–22, doi:10.1093/geront/46.1.14, pmid:16452280.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Coupland C,
    2. Dhiman P,
    3. Morriss R,
    4. et al.
    (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343, doi:10.1136/bmj.d4551, pmid:21810886. d4551.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Royal College of Psychiatrists
    (2013) Second round of the National Audit of Psychological Therapies for Anxiety and Depression (NAPT). National Report November 13. https://www.hqip.org.uk/wp-content/uploads/2018/02/UiJuO5.pdf. 28 Jan 2021.
  31. 31.↵
    1. Hansen DG,
    2. Søndergaard J,
    3. Vach W,
    4. et al.
    (2004) Socio-economic inequalities in first-time use of antidepressants: a population-based study. Eur J Clin Pharmacol 60(1):51–55, doi:10.1007/s00228-003-0723-y, pmid:14968270.
    OpenUrlCrossRefPubMed
  32. 32.
    1. Andersen I,
    2. Thielen K,
    3. Nygaard E,
    4. et al.
    (2009) Social inequality in the prevalence of depressive disorders. J Epidemiol Community Health 63(7):575–581, doi:10.1136/jech.2008.082719, pmid:19293167.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Butterworth P,
    2. Olesen SC,
    3. Leach LS
    (2013) Socioeconomic differences in antidepressant use in the PATH Through Life Study: evidence of health inequalities, prescribing bias, or an effective social safety net? J Affect Disord 149(1–3):75–83, doi:10.1016/j.jad.2013.01.006, pmid:23394713.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Hetlevik Øystein,
    2. Garre-Fivelsdal G,
    3. Bjorvatn B,
    4. et al.
    (2019) Patient-reported depression treatment and future treatment preferences: an observational study in general practice. Fam Pract 36(6):771–777, doi:10.1093/fampra/cmz026, pmid:31215999.
    OpenUrlCrossRefPubMed
Back to top

In this issue

BJGP Open
Vol. 5, Issue 2
April 2021
Download PDF
Download PowerPoint
Email Article
Citation Tools
GPs’ drug treatment for depression by patients’ educational level: registry-based study
Anneli Borge Hansen, Valborg Baste, Oystein Hetlevik, Inger Haukenes, Tone Smith-Sivertsen, Sabine Ruths
BJGP Open 2021; 5 (2): BJGPO-2020-0122. DOI: 10.3399/BJGPO-2020-0122
del.icio.us logo Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords

Intended for Healthcare Professionals

 
 

British Journal of General Practice